Current Situation20 Aug 2019 10:18
Facts Reminder..I wrote previously and added a couple of new developments..
1.motif main issue is to raise funds which will be known once the fda and motif reach an understanding of the additional trial requirement Which will be known next month.
2.raising funds for a company of future investment blockbuster AB which can generate huge income is a very attractive proposition for many bigger fish to take seriously.
3. Motif is not selling a failing product or raising cash to prompt up a failing company.
4.No warning signs of top management resigning or leaving for a better opportunity.
5.new high profile recruitment Andrew Powell with his reputed success in M&A and surely there must be a purpose of bringing him in and why would he accepts the new position after fda turned down the nda? Surely he would not tarnish his good reputation in the knowledge that motif is going under...seems daft and nonsensical.
6.No signs of auditors,brokers leaving. All staying put with Motif.
7. From the ceo latest interview, webcast...he reassured that a clear path forwards was in place and all bases are covered. Why would he say all this ...obviously not that naive to trying to deceive everyone and destroy the company he was trying to build his reputation on with others in top management. This will be considered market manipulation and abuse that could land him being investigated and in jail for up to 7 years!
8. Again in his last interview he confirmed interesting third parties in usa and outside with ongoing discussions with motif.
9.motif product has been successful in all trials undergone by motif and no death,no efficacy problem or inferiority,no liver damage detection in these trials which were done and as we all understood all were conducted in the prior knowledge of the fda discussion with motif.
10. The need for a new AB like Iclaprim is dire so why raising funds should be a problem at this stage of one more step to success.
11. Why do we think that Iclaprim might fail in another trial while it passed in every past one!?
12.for any third party this is an ideal situation for them to take advantage of motif current weakness and invest for future needed product that can generate huge income.
13.we need to remember that the fda did not reject the nda or Iclaprim but encouraged motif for another trial before approval so I read this as they wanted it to be approved but more data is required to be sure of potential liver toxicity...
14. Big ii are still holding ....
15. Lender Hercules agreed to postpone its debts which a sign of something positive is expected.
16.Yesterday rns was good news for us investors that outside government identity funds ,given to fund Iclaprim in the treatment of Listeria infection. This indicates big interest in Motif Iclaprim AB.
Chin up ,remain positive and ignore the trolls whose interest to see you selling your holdings and collapse of the company to line their pockets as they have taken short positions on Motif.
Sign In
Follow the stocks
